5402222026-01-012026-03-315402222026-03-315402222025-03-315402222025-04-012026-03-315402222026-01-012026-03-31in-capmkt:OtherExpenses1Member5402222025-04-012026-03-31in-capmkt:OtherExpenses1Member5402222026-03-31OtherNoncurrentFinancialAssetsDomain15402222026-03-31OtherNoncurrentAssetsDomain15402222026-03-31OtherCurrentFinancialAssetsDomain15402222026-03-31OtherCurrentAssetsDomain15402222026-03-31OtherNoncurrentFinancialLiabilitiesDomain15402222026-03-31OtherNoncurrentLiabilitiesDomain15402222026-03-31OtherCurrentFinancialLiabilitiesDomain15402222026-03-31OtherCurrentLiabilitiesDomain15402222026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25402222026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35402222025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25402222025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35402222026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15402222025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15402222026-01-012026-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares540222LAURUSLABSNOTLISTEDINE947Q01028LAURUS LABS LIMITEDMain BoardEquity2025-04-012026-03-312026-04-302026-04-09INRCroresQuarterlyFourth quarterSingle segmentManufacturer of Generics API, Generics FDF, Synthesis and Bio Technology2026-04-3014:00:002026-04-3015:00:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31UnauditedConsolidated18115700000118000000182337000007928600000482400000-141000000023585000004044000001221000000363510000014620000000361370000003613700000781300000133000007946000000281910000000018000002820900000208000002841700000279140000029500000281230000029400000107970000025.175.17005.175.170001.The above consolidated financial results of Laurus Labs Limited including its subsidiaries Collectively known as the Group and its associates and joint venture (as mentioned in note 3 has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on April 30 2026. The results for the year ended March 31 2026 has been audited and for the quarter ended March 31 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31 2026 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31 2026. <BR> 2.These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India. <BR> 3. The consolidated financial results include the results of the following entities Please view table from results pdf <BR> 4.The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited in India on December 01 2022. LSCPL has not commenced its operations. During the quarter ended December 31 2025 the company has invested INR 35 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited Parent Company, Eight Roads Ventures and F-Prime Capital. <BR> 5.Pursuant to investment agreement entered into by the Company with Kurnool Renewables Private Limited capital contributions have been made into Kurnool Renewables in terms of the aforesaid agreement during the quarter ended June 30 2025 . The Company has accounted for its investment in Kurnool Renewables as an associate wef May 12 2025. <BR> 6.The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments. <BR> 7.The Board of Directors of the Company in its meeting held on August 21 2025, approved the proposed Composite Scheme of Arrangement for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company subject to the necessary approval from National Company Law Tribunal, Amaravathi under section 230 and 232 of the Companies Act 2013 and other applicable provisions of the Act and the rules made thereunder. The Company have filed the Scheme with the Honble National Company Law Tribunal, Amaravati Bench at Amaravati, Andhra Pradesh, and accordingly the implementation of the Scheme is subject to the final approvals and sanctions of the applicable authorities. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01 2026 or such other date as the NCLT may approve. Pending such approval, the consolidated financial results of the Company for the quarter and year ended March 31 2026, quarter ended December 31 2025 quarter and year ended March 31 2025 are presented without giving effect to the said merger. <BR> 8.During the year ended March 31 2026 the Company allotted 604,091 equity shares of INR2 each consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <BR> 9.The Board of Directors, at their meeting held on April 30 2026 approved for the payment of interim dividend of INR 1.20 per equity share of INR each. <BR> 10.On November 21 2025, the Government of India notified four Labour Codes, effective immediately, replacing the existing 29 labour laws. In accordance with Ind AS 19 Employee benefits changes to employee benefit plans arising from legislative amendments are treated as plan amendments, requiring immediate recognition of past service cost in the Statement of Profit and Loss. This approach is consistent with the guidance issued by the lnstitute of Chartered Accountants of India.The Group has concluded its salary restructuring exercise in compliance with the new Labour Codes. The implementation of these codes resulted in an increase of INR 12.62 crores and INR 8.30 crores for the quarters ended March 31 2026 and December 31 2025 respectively, and a total of INR20.92 crores for the year ended March 31 2026. This increase pertains to the provision for gratuity and the remeasurement of leave encashment which has been recognised as an employee benefit expense. The Group continues to monitor the finalisation of Central and State Rules as well as Government clarifications regarding other aspects of the Labour Codes. <BR> 11.The figures for the current quarter and quarter ended March 31 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31 2026 and March 31 2025 respectively and published year to date figures up to third quarter ended December 31 2025 and December 31 2024 respectively which are subject to limited review by the statutory auditors.2025-04-012026-03-31AuditedConsolidated6812900000054950000068678500000279434000001725600000-27144000008954500000170730000048005000001444280000056859700000118188000000118188000002975200000-5490000029203000000889850000000029000008901400000-590000008842400000888790000013500000882900000013400000107970000025192090000016.4716.450016.4716.45000other expenses3635100000other expenses1444280000038732300000773280000002463000000184000000000309270000000442600000353530000024400000414800000056819800000234216000000215504000001126600000104000009300000321000002272880000002141700000482921000001051119000001079700000519209000005300060000013130000005431360000061134000000001321200000743460000013209000002938000000539470000014444000000178615000005120000001200890000012520900000343080000033813200000161950000037890000054270000003635430000050798300000105111900000Other non-current financial assets442600000Other non-current assets4148000000Other current financial assets32100000Other current assets2141700000Other non-current financial liabilities1321200000Other non-current liabilities5394700000Other current financial liabilities3430800000Other current liabilities16195000000-4056000000-1810300000002480000003126300000002742800000000480050000000000-25890000006570000010940000000748000000-1230000004898600000167174000000-164850000002938600000807700000162350000000267200000000490000000006810000010699500000000000000000000000657000000436300000-108866000000000002000000000276700000326870000013500000086330000017069000000250000000-5247200000101200000300000001312000009954000001126600000Remeasurement gains/(losses) on defined benefit plans64500000Income tax relating to items that will not be reclassified to profit or loss in subsequent periods-16200000Share in other comprehensive income of associates and joint venture, net oftax120000049500000Remeasurement gains/(losses) on defined benefit plans36400000Income tax relating to items that will not be reclassified to profit or loss in subsequent periods-9100000Share in other comprehensive income of associates and joint venture, net oftax11000002840000000Exchange differences on translating the financial statements of foreign operations-28700000-28700000Exchange differences on translating the financial statements of foreign operations-87400000-874000000020800000-59000000AuditedtrueDeloitte Haskins and Sells LLPtrue2027-07-31